Biothera Drug Synergistic with Avastin(R) Against Cancer, Study Finds
Biothera’s Imprime PGG™ increased the effectiveness of Avastin® (bevacizumab), a monoclonal antibody approved for the treatment of metastatic colorectal, breast and non-small cell lung cancer, according to a new preclinical study published in the current issue of Clinical Cancer Research.
This entry was posted on Friday, February 29th, 2008 at 10:04 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.